Journal Article
. 2020 May;20(1).
doi: 10.1186/s12885-020-06939-6.

PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer

Lutfi H Alfarsi 1 Rokaya El Ansari 1 Madeleine L Craze 1 Brendah K Masisi 1 Ian O Ellis 1 Emad A Rakha 1 Andrew R Green 2 
Affiliations
  • PMID: 32410585
  •     34 References

Abstract

Background: PPFIA1 is an important regulator of cell migration and invasion, regulating focal adhesion signalling and disassembly. PPFIA1 is frequently amplified in breast cancer, and recent functional studies indicate that PPFIA1 is an important promoter of migration and invasion in breast cancer. This study aims to evaluate the utility of PPFIA1 expression in the luminal breast cancer as a prognostic marker to predict the response to endocrine therapy.

Methods: Large, well-characterised cohorts of primary luminal breast cancer patients with long-term follow-up was assessed for the clinical impact of PPFIA1 expression at the transcriptomic and proteomic levels. Prognostic significance of PPFIA1 and its relationship with clinical outcome and benefit of endocrine therapy were analysed. In addition, its association with other related-genes was analysed.

Results: There was significant association between PPFIA1 expression and a member of the liprin family that involves in cell invasion (PPFIBPI), and the cell cycle regulator (CCND1), whereas a negative association was observed with the tumour suppressor gene (CD82). Patients with high PPFIA1 expression were associated with high risk of recurrence, distant metastasis and death from breast cancer (P < 0.05). Importantly, high PPFIA1 expression predicted relapse in a subset of patients who were subject to endocrine treatment alone, and was an independent prognostic marker of unfavourable outcome in these patients (P < 0.05).

Conclusions: These findings support the proposed role for PPFIA1 as a regulator of cell migration in breast cancer and provides definitive evidence for the clinical utility of PPFIA1 expression in patients with luminal breast cancer. Most importantly, our data suggests that PPFIA1 might be a potential predictive marker for poor benefit from endocrine therapy.

Keywords: Breast cancer; Endocrine resistance; Liprin; Oestrogen receptor; PPFIA1; Predictive biomarker.

bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer.
Pascal Jézéquel, Mario Campone, +4 authors, Loïc Campion.
Breast Cancer Res Treat, 2011 Apr 01; 131(3). PMID: 21452023
Highly Cited.
Tumour-cell invasion and migration: diversity and escape mechanisms.
Peter Friedl, Katarina Wolf.
Nat Rev Cancer, 2003 May 02; 3(5). PMID: 12724734
Highly Cited. Review.
Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
Emad A Rakha, Maysa E El-Sayed, +7 authors, Ian O Ellis.
J Clin Oncol, 2007 Sep 19; 25(30). PMID: 17876012
Liprin-α1 regulates breast cancer cell invasion by affecting cell motility, invadopodia and extracellular matrix degradation.
V Astro, C Asperti, +3 authors, I de Curtis.
Oncogene, 2010 Dec 15; 30(15). PMID: 21151172
Liprin-alpha1 affects the distribution of low-affinity beta1 integrins and stabilizes their permanence at the cell surface.
Claudia Asperti, Emanuela Pettinato, Ivan de Curtis.
Exp Cell Res, 2010 Jan 26; 316(6). PMID: 20096687
Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients.
M Stendahl, A Kronblad, +3 authors, G Landberg.
Br J Cancer, 2004 May 13; 90(10). PMID: 15138475    Free PMC article.
Liprin-α1 modulates cancer cell signaling by transmembrane protein CD82 in adhesive membrane domains linked to cytoskeleton.
Henna Pehkonen, Mira Lento, +4 authors, Outi Monni.
Cell Commun Signal, 2018 Jul 15; 16(1). PMID: 30005669    Free PMC article.
Endocrine resistance in breast cancer--An overview and update.
Robert Clarke, John J Tyson, J Michael Dixon.
Mol Cell Endocrinol, 2015 Oct 13; 418 Pt 3. PMID: 26455641    Free PMC article.
Highly Cited. Review.
Amplification and overexpression of PPFIA1, a putative 11q13 invasion suppressor gene, in head and neck squamous cell carcinoma.
Kaia Davis Tan, Yansong Zhu, +8 authors, Patrick Tan.
Genes Chromosomes Cancer, 2008 Jan 16; 47(4). PMID: 18196592
Liprins, a family of LAR transmembrane protein-tyrosine phosphatase-interacting proteins.
C Serra-Pagès, Q G Medley, +2 authors, M Streuli.
J Biol Chem, 1998 Jun 23; 273(25). PMID: 9624153
Liprin-alpha1 promotes cell spreading on the extracellular matrix by affecting the distribution of activated integrins.
Claudia Asperti, Veronica Astro, +2 authors, Ivan de Curtis.
J Cell Sci, 2009 Aug 20; 122(Pt 18). PMID: 19690048
Inhibitor of growth 4 suppresses cell spreading and cell migration by interacting with a novel binding partner, liprin alpha1.
Jiang-Cheng Shen, Motoko Unoki, +5 authors, Curtis C Harris.
Cancer Res, 2007 Mar 17; 67(6). PMID: 17363573    Free PMC article.
A new genome-driven integrated classification of breast cancer and its implications.
Sarah-Jane Dawson, Oscar M Rueda, Samuel Aparicio, Carlos Caldas.
EMBO J, 2013 Feb 12; 32(5). PMID: 23395906    Free PMC article.
Highly Cited. Review.
Current issues with luminal subtype classification in terms of prediction of benefit from endocrine therapy in early breast cancer.
Lutfi Alfarsi, Simon Johnston, +2 authors, Andrew R Green.
Histopathology, 2018 Apr 01; 73(4). PMID: 29603357
Review.
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration.
Willi Sauerbrei, Sheila E Taube, +2 authors, Douglas G Altman.
J Natl Cancer Inst, 2018 Jun 07; 110(8). PMID: 29873743    Free PMC article.
Highly Cited. Review.
Liprin-α1 is a regulator of vimentin intermediate filament network in the cancer cell adhesion machinery.
Henna Pehkonen, Pernilla von Nandelstadh, +4 authors, Outi Monni.
Sci Rep, 2016 Apr 15; 6. PMID: 27075696    Free PMC article.
An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients.
Balazs Györffy, Andras Lanczky, +4 authors, Zoltan Szallasi.
Breast Cancer Res Treat, 2009 Dec 19; 123(3). PMID: 20020197
Highly Cited.
Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Jie Yuan, Manran Liu, +8 authors, Guanglun Yang.
Breast Cancer Res, 2015 May 21; 17. PMID: 25990368    Free PMC article.
Function of liprins in cell motility.
Ivan de Curtis.
Exp Cell Res, 2010 Sep 30; 317(1). PMID: 20875404
Review.
PPFIA1 and CCND1 are frequently coamplified in breast cancer.
Ana-Maria Dancau, Laura Wuth, +11 authors, Ronald Simon.
Genes Chromosomes Cancer, 2009 Sep 30; 49(1). PMID: 19787783
PPFIA1 is upregulated in liver metastasis of breast cancer and is a potential poor prognostic indicator of metastatic relapse.
Jing Yang, Ning-Ni Wu, +5 authors, Wen-Ling Song.
Tumour Biol, 2017 Jul 20; 39(7). PMID: 28720060
KAI1/CD82, a tumor metastasis suppressor.
Wei M Liu, Xin A Zhang.
Cancer Lett, 2005 Nov 02; 240(2). PMID: 16260083
Review.
Prognostic relevance of gene amplifications and coamplifications in breast cancer.
Khawla Al-Kuraya, Peter Schraml, +13 authors, Guido Sauter.
Cancer Res, 2004 Dec 03; 64(23). PMID: 15574759
Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM).
M J Duffy, N Harbeck, +4 authors, F Cardoso.
Eur J Cancer, 2017 Mar 05; 75. PMID: 28259011
Highly Cited. Review.
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
Joseph A Sparano, Robert J Gray, +27 authors, George W Sledge.
N Engl J Med, 2019 Jun 04; 380(25). PMID: 31157962    Free PMC article.
Highly Cited.
Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification.
Karin Jirström, Maria Stendahl, +4 authors, Göran Landberg.
Cancer Res, 2005 Sep 06; 65(17). PMID: 16140974
Histochemical approaches to steroid receptor analyses.
K S McCarty, K S McCarty.
Semin Diagn Pathol, 1984 Nov 01; 1(4). PMID: 6400637
Review.
PPFIA1 drives active α5β1 integrin recycling and controls fibronectin fibrillogenesis and vascular morphogenesis.
Giulia Mana, Fabiana Clapero, +11 authors, Donatella Valdembri.
Nat Commun, 2016 Nov 24; 7. PMID: 27876801    Free PMC article.
CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy.
Lutfi H Alfarsi, Rokaya El Ansari, +5 authors, Andrew R Green.
Breast Cancer Res Treat, 2019 Sep 01; 178(3). PMID: 31471836
Effects of the scaffold proteins liprin-α1, β1 and β2 on invasion by breast cancer cells.
Sara Chiaretti, Veronica Astro, Elena Chiricozzi, Ivan de Curtis.
Biol Cell, 2015 Dec 15; 108(3). PMID: 26663347
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), C Davies, +11 authors, R Peto.
Lancet, 2011 Aug 02; 378(9793). PMID: 21802721    Free PMC article.
Highly Cited.
Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo.
Catherine C Park, Hui Zhang, +4 authors, Mina J Bissell.
Cancer Res, 2006 Feb 03; 66(3). PMID: 16452209    Free PMC article.
Highly Cited.
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.
Christina Curtis, Sohrab P Shah, +29 authors, Samuel Aparicio.
Nature, 2012 Apr 24; 486(7403). PMID: 22522925    Free PMC article.
Highly Cited.
Overexpression of KAI1 suppresses in vitro invasiveness and in vivo metastasis in breast cancer cells.
X Yang, L L Wei, +3 authors, M E Lippman.
Cancer Res, 2001 Jun 30; 61(13). PMID: 11431371